

Award Number: W81XWH-19-1-0588

Title:

Investigating the Expression, Role, and Targeting of Collagen Modifying Prolyl 4-Hydroxylase P4HA1 in Prostate Cancer Progression and Metastasis

Principal Investigator: **Sooryanarayana Varambally**

Contracting Organization: **University of Alabama at Birmingham**

Report Date: OCTOBER 2022

Type of Report: **Annual Report**

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE : OCTOBER 2022		2. REPORT TYPE: Annual		3. DATES COVERED 30SEPT2021 - 29SEPT2022	
4. TITLE AND SUBTITLE Investigating the Expression, Role, and Targeting of Collagen Modifying Prolyl 4-Hydroxylase P4HA1 in Prostate Cancer Progression and Metastasis				5a. CONTRACT NUMBER W81XWH-19-1-0588	
				5b. GRANT NUMBER W81XWH-19-1-0588	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sooryanarayana Varambally E-Mail:svarambally@uabmc.edu				5d. PROJECT NUMBER 0011332541	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Alabama at Birmingham Department of Pathology WTI 420B 1824 6th Avenue South Birmingham, AL 35294-3300				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer mortality of men in the United States. Complex molecular and signaling events converge leading to PCa initiation, unregulated growth, invasion, and metastasis. There is a growing concern that PSA screening leads to over-diagnosis resulting in excessive treatment of indolent PCa without significant clinical benefit. Thus identification and validation of novel diagnostic and prognostic molecular biomarkers of PCa as well as the oncogenic therapeutic targets are of critical importance for the early detection, management, and cure of PCa. Our recent studies utilizing gene expression profiling and next generation sequencing of prostate cancer tissues identified prolyl hydroxylase P4HA1, a key enzyme in collagen modification resulting in extracellular matrix modification in cancer as upregulated in primary PCa and castration resistant PCa. Being an enzyme, P4HA1 is a viable therapeutic target amenable to small molecule inhibition.					
15. SUBJECT TERMS NONE LISTED					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

COVER.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
BODY.....	5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6-7

Title of the Grant: Investigating the Expression, Role, and Targeting of Collagen Modifying Prolyl 4-Hydroxylase P4HA1 in Prostate Cancer Progression and Metastasis

Award Number: W81XWH1910588

Principal Investigator: Sooryanarayana Varambally

Annual Report: 10/30/2021- 9/29/2022

INTRODUCTION

Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer mortality of men in the United States. Complex molecular and signaling events converge leading to PCa initiation, unregulated growth, invasion, and metastasis. There is a growing concern that PSA screening leads to over-diagnosis resulting in excessive treatment of indolent PCa without significant clinical benefit. Thus identification and validation of novel diagnostic and prognostic molecular biomarkers of PCa as well as the oncogenic therapeutic targets are of critical importance for the early detection, management, and cure of PCa. Our recent studies utilizing gene expression profiling and next generation sequencing of prostate cancer tissues identified prolyl hydroxylase P4HA1, a key enzyme in collagen modification resulting in extracellular matrix modification in cancer as upregulated in primary PCa and castration resistant PCa. Being an enzyme, P4HA1 is a viable therapeutic target amenable to small molecule inhibition.

SPECIFIC AIMS:

Aim1. Evaluate the significance of P4HA1 expression in PCa.

Aim2. Investigate the functional role of P4HA1 in PCa metastasis.

Aim3. Targeting P4HA1 in PCa using specific small molecule inhibitor.

BODY

We have shown earlier that the P4HA1 expression in multiple prostate cancer datasets and identified its overexpression. The gene expression of P4HA1 is increased in prostate cancer samples compared to benign prostate cells.

Furthermore, we have performed immunohistochemical analysis to detect and quantify P4HA1 protein expression in prostate cancer tissues. We used prostate cancer tissue microarray (TMA) for this. The staining showed increased P4HA1 protein in prostate cancer tissues in both Caucasian and African American prostate cancer tissues. The staining intensity has been quantified biostatistical analysis is being performed. During the current funding period, we have performed multiple in vitro and in vivo experiments to test the effect of P4HA1 overexpression

Treatment of prostate cancer cells DU145 and PC3 with P4HA1 inhibitor PythiDc resulted in reduced prostate cancer cell proliferation (Fig. 1 A, B) and colony formation (Fig. 1 C).

At the molecular level, overexpression of P4HA1 in normal prostate epithelial cells PrEC, it lead to increase in expression of MMP1 and PCNA, upregulates mesenchymal markers N-Cadherin and Vimentin and downregulates epithelial marker E-cadherin (Fig. 2A). Treating prostate cancer cells with P4HA1 PythiDC resulted in downregulation of AGO2 and MMP1 expression (Fig. 2B) and modulation of epithelial mesenchymal Transition (EMT) markers (Fig. 2C).

Next, we utilized mouse models to study the effectiveness of PythiDC in regulating prostate tumor growth using immunocompromised mice. We used PC3 and DU145 PCa cell lines. As




Figure 1: PythiDC inhibit the proliferation of A) DU145 and B) PC3 PCa cells. Colony assay for DU145 and PC3 cells. Cells were treated with PythiDC and stained with crystal violet.




Figure 2: Modulation of P4HA1 or blocking with PythiDC treatment results in multiple molecular changes including EMT changes in prostate cancer cells. A. PrEC cells were infected with P4HA1 or control vector. Expression of P4HA1, MMP1, N-cadherin, vimentin, E-cadherin, and PCNA were determined by western blot analysis. **B.** DU145 and PC3 cells were treated with P4HA1 inhibitor diethyl-phythiDC (25-100 μM) for 48 hrs and protein lysates were prepared for western blot analysis. Expression of P4HA1, AGO2, and MMP1 were measured using specific antibodies. **C.** Expression of N-cadherin, Vimentin and E-cadherin in DU145 and PC3 cells after treatment. Equal loading of protein was confirmed by stripping the membrane and re-probing it for β-actin.


shown in photographs (**Fig 3A and B**), there is a reduction in tumor size upon treating mice with P4HA1 inhibitor. Quantification of tumor weight (**Fig 3C and D**) after treatment with vehicle and

diethyl-pythiDC at the time of termination of experiment showed statistically significant reduction in the tumor weight after treatment with PythiDC. Furthermore, pythiDC treatment modulates EMT markers in tumors of immunocompromised mice subcutaneously injected with PC3 and DU145 cells (**Fig 3E and F**).

KEY RESEARCH

ACCOMPLISHMENTS:

- Analyzed multiple prostate cancer datasets to evaluate the expression of P4HA1 and other enzymes related to collagen metabolism
- Analyzed the effect of P4HA1 inhibitor PythiDC on cell proliferation, colony formation, and EMT markers
- Studied the effect of P4HA1 overexpression in PrEC cells on EMT markers, MMP1, and PCNA
- Performed *In vivo* tumor xenograft studies and investigated the effect of P4HA1 inhibitor PythiDC
- Investigated the molecular changes upon treatment of tumors with PythiDC



REPORTABLE OUTCOMES

None

CONCLUSIONS

We have initiated the proposed studies and finished analyzing the genomic and transcriptomic data showing the overexpression of P4HA1 in PCa. We also have PCa TMA ready constructed by our collaborator Dr. George Netto. We finished standardizing the immunohistochemical staining of prostate TMA's using P4HA1 specific antibodies. The staining was evaluated by expert pathologist and is being evaluated by statistician to fund the correlation between P4HA1

staining intensity and prostate cancer progression. During the current funding period, we have performed *in vivo* tumor growth studies and evaluated the effect of P4HA1 inhibitors in PCa tumor growth. We will be evaluating the TMA immunostaining data and the PCa metastasis data in the coming period.

PERSONNEL RECEIVING PAY FROM THIS GRANT

Sooryanarayana Varambally, Ph.D.

George Netto, M.D.

Sejong Bae, Ph.D.

Selvarangan Ponnazhagan, Ph.D.

Darshan Shimoga Chandrashekar, Ph.D., Postdoctoral fellow

Farrukh Afaq, Ph.D., Research Associate

SanthoshKumar Karthikeyan, MS, Student.

Note: The beginning of COVID19 pandemic did effect to an extent some of the proposed experimental work and the timeline of the performance. We will continue and finish the remaining part of the project during this year and if allowed, will request no cost extension if need arises.